97. Ulcerative colitis Clinical trials / Disease details


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02318667
(ClinicalTrials.gov)
February 27, 201512/12/2014Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.Colitis, UlcerativeBiological: GolimumabMerck Sharp & Dohme Corp.NULLCompleted18 Years65 YearsAll38Phase 4Portugal
2NCT02155335
(ClinicalTrials.gov)
July 1, 20142/6/2014Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative ColitisUlcerative ColitisDrug: Prefilled Syringe delivery of Golimumab;Drug: Smartject Device delivery of GolimumabMerck Sharp & Dohme Corp.NULLCompleted18 YearsN/AAll100Phase 4Belgium
3EUCTR2014-000656-29-BE
(EUCTR)
13/06/201405/03/2014Study to evaluate delivery preference of Simponi (golimumab) by Ulcerative Colitis patients: delivery using a prefilled syringe or the Smartject™ devicePreference for a prefilled syringe or Smartject™ device for delivering SIMPONI (golimumab) in patients suffering from moderate to severe ulcerative colitis - SMART Ulcerative Colitis
MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
Trade Name: Simponi® (Golimumab)
Product Name: Simponi (Golimumab)
Product Code: MK-8259
INN or Proposed INN: GOLIMUMAB
Other descriptive name: Simponi
Trade Name: Simponi® (Golimumab)
Product Name: Simponi (Golimumab)
Product Code: MK-8259
INN or Proposed INN: GOLIMUMAB
Other descriptive name: Simponi
MSD Belgium BVBA/SPRLNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Belgium
4NCT02092285
(ClinicalTrials.gov)
May 9, 201418/3/2014Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative ColitisUlcerative ColitisDrug: GolimumabMerck Sharp & Dohme Corp.NULLCompleted18 YearsN/AAll205Phase 4United Kingdom